Biomarkers in Samples From Young Patients With Soft Tissue Sarcoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01342783|
Recruitment Status : Completed
First Posted : April 27, 2011
Last Update Posted : May 18, 2016
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
PURPOSE: This research trial is studying biomarkers in samples from young patients with soft tissue sarcoma.
|Condition or disease||Intervention/treatment|
|Sarcoma||Genetic: DNA analysis Genetic: RNA analysis Genetic: mutation analysis Genetic: nucleic acid sequencing Other: laboratory biomarker analysis|
- To identify the key components of driver pathways of primary and secondary soft tissue sarcomas.
- To perform the next-generation sequencing on primary versus normal on undifferentiated sarcomas.
OUTLINE: Genomic DNA and RNA samples from undifferentiated sarcoma tumors are analyzed by next-generation sequencing for somatic mutations. Normal matched lymphocytes and tissue are also analyzed.
|Study Type :||Observational|
|Estimated Enrollment :||20 participants|
|Official Title:||Next Generation Sequencing of Childhood Soft Tissue Sarcomas to Identify Drivers of Primary and Metastatic Disease|
|Study Start Date :||May 2011|
|Actual Primary Completion Date :||May 2016|
- Occurrence of somatic mutations in driver genes and mutations in other genes that occur individually
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01342783
|Principal Investigator:||Poul Sorensen, MD, PhD||British Columbia Cancer Agency|